Senseonics Holdings, Inc. (SENS) — SEC Filings
Senseonics Holdings, Inc. (SENS) — 38 SEC filings. Latest: 8-K (May 7, 2026). Includes 21 8-K, 6 10-Q, 4 DEF 14A.
View Senseonics Holdings, Inc. on SEC EDGAR
Overview
Senseonics Holdings, Inc. (SENS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: Senseonics Holdings, Inc. reported a significant increase in total revenue for the nine months ended September 30, 2025, reaching $21.001 million, up from $14.175 million in the prior year period. This was driven by a substantial rise in direct revenue to $9.235 million from $2.322 million, while re
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 2 bearish, 35 neutral, 1 mixed. The dominant filing sentiment for Senseonics Holdings, Inc. is neutral.
Filing Type Overview
Senseonics Holdings, Inc. (SENS) has filed 21 8-K, 1 DEFR14A, 1 ARS, 6 10-Q, 4 DEF 14A, 1 8-K/A, 2 10-K, 1 DEFA14A, 1 SC 13G/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of SENS's 32 recent filings, 3 were flagged as high-risk, 14 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $21.001M |
| Net Income | -$48.290M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $111.0M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Steven Edelman M.D.
- Edward J. Fiorentino
- Anthony Raab
- Dr. Jonathan L. Weitz
- Dr. David J. Tolmie
- Timothy J. Scannell
- Michael F. P. Allen
Industry Context
Senseonics operates in the highly competitive medical technology sector, specifically focusing on the continuous glucose monitoring (CGM) market. This market is characterized by rapid innovation and the presence of established players offering both disposable and implantable solutions. Key trends include the increasing adoption of CGM devices by diabetic patients for better disease management and the ongoing development of more accurate, longer-lasting, and user-friendly systems.
Top Tags
financial-reporting (5) · debt (5) · proxy-statement (4) · sec-filing (3) · governance (3) · SEC Filing (3) · corporate-governance (3) · 8-k (3) · financials (3) · financial-condition (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue | $21.001M | for the nine months ended September 30, 2025, up from $14.175M in 2024 |
| Net Loss | $48.290M | for the nine months ended September 30, 2025, an improvement from $63.140M in 2024 |
| Accumulated Deficit | $996.2M | as of September 30, 2025, indicating significant historical losses |
| Unrestricted Cash, Cash Equivalents and Marketable Securities | $111.0M | as of September 30, 2025, providing liquidity |
| Amended Loan Commitment | $100.0M | increased from $50.0M with Hercules Capital, Inc. |
| Public Offering Gross Proceeds | $57.5M | from the sale of 5,750,000 shares of common stock in May 2025 |
| Private Placement Purchase Price | $20.3M | from Abbott Laboratories for 2,026,963 shares of common stock |
| Reverse Stock Split Ratio | 1-for-20 | effected on October 17, 2025 |
| Common Stock Shares Outstanding | 40,858,460 | as of October 31, 2025, post-reverse stock split |
| Total Stockholders' Equity | $78.165M | as of September 30, 2025, a significant improvement from a deficit of ($16.555M) at December 31, 2024 |
| Revenue | $4.1M | Decreased by 8.9% from $4.5M in Q2 2024, showing declining sales. |
| Capital Raised | $13.8M | Gross proceeds from Series B Preferred Stock offering in May 2025, crucial for liquidity. |
| Revenue Decrease | 8.9% | Percentage decline in revenue from Q2 2024 to Q2 2025. |
| Total Assets | $595.4M | As of March 31, 2025 |
| Total Liabilities | $654.2M | As of March 31, 2025 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Senseonics Holdings, Inc. (SENS)?
Senseonics Holdings, Inc. has 38 recent SEC filings from Jan 2024 to May 2026, including 21 8-K, 6 10-Q, 4 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SENS filings?
Across 38 filings, the sentiment breakdown is: 2 bearish, 35 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Senseonics Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Senseonics Holdings, Inc. (SENS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Senseonics Holdings, Inc.?
Key financial highlights from Senseonics Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SENS?
The investment thesis for SENS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Senseonics Holdings, Inc.?
Key executives identified across Senseonics Holdings, Inc.'s filings include Steven Edelman M.D., Edward J. Fiorentino, Anthony Raab, Dr. Jonathan L. Weitz, Dr. David J. Tolmie and 2 others.
What are the main risk factors for Senseonics Holdings, Inc. stock?
Of SENS's 32 assessed filings, 3 were flagged high-risk, 14 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Senseonics Holdings, Inc.?
Forward guidance and predictions for Senseonics Holdings, Inc. are extracted from SEC filings as they are enriched.